Zomedica Corp. (ZOMDF) shareholders
Close on Oct 19, 2026Market cap $77.40MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ZOMDF | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ancora Advisors, LLC | 83,610 | 0.01% | $8.35K | – | 0.00% |
| CoreCap Advisors, LLC | 4,800 | 0.00% | $480 | – | 0.00% |
| Gill Capital Partners, LLC | 2,719 | 0.00% | $272 | – | 0.00% |
| Harbour Investments, Inc. | 2,200 | 0.00% | $220 | – | 0.00% |
| EverSource Wealth Advisors, LLC | 1,000 | 0.00% | $100 | New | 0.00% |
| Bogart Wealth, LLC | 680 | 0.00% | $68 | – | 0.00% |
| Farther Finance Advisors, LLC | 86 | 0.00% | $9 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 7 | 0M | 0.0% | 2 / 0 | 0 / 3 | 0M | 1M |
| Q1 2026 | 8 | 1M | 0.1% | 2 / 2 | 1 / 1 | 0M | 0M |
| Q4 2025 | 7 | 1M | 0.1% | 1 / 0 | 2 / 3 | 0M | 1M |
| Q3 2025 | 9 | 2M | 0.2% | 2 / 0 | 2 / 3 | 1M | 4M |
| Q2 2025 | 10 | 5M | 0.5% | 2 / 1 | 2 / 14 | 0M | 1M |
| Q1 2025 | 23 | 7M | 0.7% | 3 / 3 | 1 / 72 | 5M | 90M |
| Q4 2024 | 92 | 92M | 9.4% | 17 / 17 | 10 / 9 | 12M | 1M |
| Q3 2024 | 85 | 81M | 8.3% | 9 / 13 | 15 / 19 | 11M | 4M |
| Q2 2024 | 97 | 85M | 8.6% | 13 / 15 | 17 / 13 | 4M | 5M |
| Q1 2024 | 98 | 85M | 8.7% | 15 / 13 | 21 / 10 | 3M | 7M |
| Q4 2023 | 93 | 89M | 9.1% | 17 / 20 | 9 / 12 | 6M | 1M |
| Q3 2023 | 88 | 84M | 8.6% | 8 / 20 | 10 / 13 | 1M | 14M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Larry C. Heaton Ii | CEO, Director | 1,250,000 | 0.13% | Nov 9, 2026 |
| Anthony K. Blair | COO | 1,000,000 | 0.10% | Aug 7, 2026 |
| Karen DeHaan-Fullerton | General Counsel | 104,300 | 0.01% | Aug 7, 2026 |
| Russell Kevin Klass | Sr Vice President, Sales | 6,105,000 | 0.62% | Aug 7, 2026 |
| Scott Jordan | Chief Financial Officer | 300,000 | 0.03% | Mar 19, 2025 |
| Christopher Ross Macleod | Director | 143,000 | 0.01% | Nov 17, 2026 |
| Pamela Nichols | Director | – | – | Nov 17, 2026 |
| Sean Whelan | Director | – | – | Nov 17, 2026 |
| Johnny D. Powers | Director | 4,425,000 | 0.45% | Nov 17, 2026 |
| Jeffrey M. Rowe | Director | 13,116,127 | 1.34% | Nov 17, 2026 |
| Robert Cohen | Director | 543,750 | 0.06% | Nov 17, 2026 |
| Rodney James Williams | Director | 301,900 | 0.03% | Nov 18, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Russell Kevin Klass Sr. Vice President, Sales | May 21, 2026 | Buy | +104,000 | $0.10 | $10.40K | 104,000 |
| Russell Kevin Klass – | May 21, 2026 | Buy | +11,399 | $0.11 | $1.25K | 5,995,500 |
| Russell Kevin Klass – | May 21, 2026 | Buy | +5,500 | $0.11 | $605 | 6,001,000 |
| Johnny D. Powers Director | May 20, 2026 | Buy | +97,515 | $0.10 | $9.75K | 4,425,000 |
| Russell Kevin Klass – | May 20, 2026 | Buy | +200,000 | $0.11 | $22.00K | 5,984,101 |
| Johnny D. Powers Director | May 19, 2026 | Buy | +2,485 | $0.10 | $249 | 4,327,485 |
| Johnny D. Powers Director | May 18, 2026 | Buy | +100,000 | $0.10 | $10.00K | 4,325,000 |
| Johnny D. Powers Director | May 13, 2026 | Buy | +200,000 | $0.11 | $22.00K | 4,225,000 |
| Johnny D. Powers Director | May 12, 2026 | Buy | +100,000 | $0.11 | $11.00K | 4,025,000 |
| Johnny D. Powers Director | May 11, 2026 | Buy | +391,129 | $0.11 | $43.02K | 3,925,000 |
| Johnny D. Powers Director | May 8, 2026 | Buy | +108,871 | $0.11 | $11.98K | 3,533,871 |
| Larry C. Heaton Ii CEO, Director | May 8, 2026 | Buy | +250,000 | $0.11 | $27.50K | 1,250,000 |
| Russell Kevin Klass Sr Vice President, Sales | Nov 13, 2025 | Buy | +150,000 | $0.10 | $15.00K | 5,784,101 |
| Russell Kevin Klass Sr Vice President, Sales | Nov 10, 2025 | Buy | +120,000 | $0.10 | $12.00K | 5,634,101 |
| Russell Kevin Klass Sr Vice President, Sales | Nov 7, 2025 | Buy | +5,000 | $0.10 | $500 | 5,514,101 |
| Russell Kevin Klass Sr Vice President, Sales | Nov 6, 2025 | Buy | +253,007 | $0.08 | $20.24K | 5,509,101 |
| Russell Kevin Klass Sr Vice President, Sales | Aug 12, 2025 | Buy | +745,341 | $0.04 | $29.81K | 5,256,094 |
| Russell Kevin Klass Sr Vice President, Sales | Aug 12, 2025 | Buy | +250,000 | $0.04 | $10.00K | 4,510,753 |
| Russell Kevin Klass Sr Vice President, Sales | Aug 11, 2025 | Buy | +60,723 | $0.04 | $2.43K | 4,260,753 |
| Russell Kevin Klass Sr Vice President of Sales | Aug 11, 2025 | Buy | +250,000 | $0.04 | $10.00K | 3,950,030 |
| Russell Kevin Klass Sr Vice President of Sales | Aug 11, 2025 | Buy | +250,000 | $0.04 | $10.00K | 4,200,030 |
| Russell Kevin Klass Sr Vice President of Sales | Aug 8, 2025 | Buy | +500,000 | $0.04 | $20.00K | 3,700,030 |
| Anthony K. Blair COO | May 21, 2025 | Buy | +63,750 | $0.05 | $3.19K | 1,000,000 |
| Anthony K. Blair COO | May 21, 2025 | Buy | +36,250 | $0.05 | $1.81K | 936,250 |
| Johnny D. Powers Director | May 19, 2025 | Buy | +500,000 | $0.05 | $25.00K | 3,425,000 |
| Karen DeHaan-Fullerton General Counsel/Corporate Secy | May 19, 2025 | Buy | +104,300 | $0.05 | $5.22K | 104,300 |
| Jeffrey M. Rowe Director | Mar 17, 2025 | Buy | +100,647 | $0.07 | $7.05K | 1,540,127 |
| Jeffrey M. Rowe Director | Mar 17, 2025 | Buy | +500,000 | $0.06 | $30.00K | 1,439,480 |
| Jeffrey M. Rowe Director | Mar 17, 2025 | Buy | +731,368 | $0.07 | $51.20K | 2,399,495 |
| Jeffrey M. Rowe Director | Mar 17, 2025 | Buy | +4,265 | $0.07 | $299 | 2,343,760 |
| Jeffrey M. Rowe Director | Mar 17, 2025 | Buy | +34,725 | $0.07 | $2.43K | 2,378,485 |
| Jeffrey M. Rowe Director | Mar 17, 2025 | Buy | +68,000 | $0.07 | $4.76K | 1,608,127 |
| Rodney James Williams Director | Mar 17, 2025 | Buy | +100,000 | $0.07 | $7.00K | 261,900 |
| Scott Jordan Chief Financial Officer | Mar 17, 2025 | Buy | +300,000 | $0.06 | $18.00K | 300,000 |
| Rodney James Williams Director | Mar 17, 2025 | Buy | +100,000 | $0.07 | $7.00K | 100,000 |
| Russell Kevin Klass Sr Vice President of Sales | Mar 17, 2025 | Buy | +699,980 | $0.07 | $49.00K | 3,200,030 |
| Jeffrey M. Rowe Director | Mar 17, 2025 | Buy | +500,000 | $0.06 | $30.00K | 775,000 |
| Jeffrey M. Rowe Director | Mar 17, 2025 | Buy | +100,647 | $0.07 | $7.05K | 875,647 |
| Jeffrey M. Rowe Director | Mar 17, 2025 | Buy | +68,000 | $0.07 | $4.76K | 943,647 |
| Jeffrey M. Rowe Director | Mar 17, 2025 | Buy | +731,368 | $0.07 | $51.20K | 1,675,015 |
| Jeffrey M. Rowe Director | Mar 17, 2025 | Buy | +34,725 | $0.07 | $2.43K | 1,714,005 |
| Jeffrey M. Rowe Director | Mar 17, 2025 | Buy | +4,265 | $0.07 | $299 | 1,679,280 |
| Johnny D. Powers Director | Mar 17, 2025 | Buy | +100,000 | $0.07 | $7.00K | 2,925,000 |
| Johnny D. Powers Director | Mar 17, 2025 | Buy | +50,000 | $0.07 | $3.50K | 2,825,000 |
| Johnny D. Powers Director | Mar 17, 2025 | Buy | +100,000 | $0.07 | $7.00K | 2,775,000 |
| Johnny D. Powers Director | Mar 17, 2025 | Buy | +100,000 | $0.07 | $7.00K | 2,675,000 |
| Johnny D. Powers Director | Mar 17, 2025 | Buy | +50,000 | $0.07 | $3.50K | 2,575,000 |
| Johnny D. Powers Director | Mar 17, 2025 | Buy | +100,000 | $0.07 | $7.00K | 2,525,000 |
| Christopher Ross Macleod Director | Mar 17, 2025 | Buy | +143,000 | $0.06 | $8.58K | 143,000 |
| Anthony K. Blair COO | Mar 17, 2025 | Buy | +500,000 | $0.06 | $30.00K | 900,000 |
| Larry C. Heaton Ii CEO, Director | Mar 17, 2025 | Buy | +118,855 | $0.06 | $7.13K | 628,855 |
| Larry C. Heaton Ii CEO, Director | Mar 17, 2025 | Buy | +191,817 | $0.06 | $11.51K | 820,672 |
| Larry C. Heaton Ii CEO, Director | Mar 17, 2025 | Buy | +179,328 | $0.06 | $10.76K | 1,000,000 |
| Larry C. Heaton Ii CEO, Director | Mar 17, 2025 | Buy | +10,000 | $0.05 | $500 | 510,000 |
| Russell Kevin Klass Vice President of Sales | Nov 11, 2024 | Buy | +289,800 | $0.12 | $34.78K | 1,500,050 |
| Russell Kevin Klass Vice President of Sales | Nov 11, 2024 | Buy | +210,200 | $0.12 | $25.22K | 1,210,250 |
| Larry C. Heaton Ii CEO, Director | Nov 11, 2024 | Buy | +100,000 | $0.12 | $12.00K | 500,000 |
| Johnny D. Powers Director | Nov 11, 2024 | Buy | +100,000 | $0.12 | $12.00K | 2,425,000 |
| Anthony K. Blair COO | Nov 8, 2024 | Buy | +150,000 | $0.12 | $18.00K | 400,000 |
| Larry C. Heaton Ii CEO, Director | Sep 5, 2024 | Buy | +100,000 | $0.13 | $13.00K | 400,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Zomedica's stock actually held short. Settlement fails (shares not delivered on time) peaked at 3,723 shares on Aug 25, 2026 over the last 90 days.
See a number that looks wrong?